Cara Therapeutics, Inc.

NasdaqCM:CARA Stok Raporu

Piyasa değeri: US$16.7m

Cara Therapeutics Geçmiş Kazanç Performansı

Geçmiş kriter kontrolleri 0/6

Cara Therapeutics şirketinin kazançları yıllık ortalama -10.4% oranında azalırken, Pharmaceuticals sektörünün kazançları yıllık 1.2% oranında artan oldu. Gelirler yıllık ortalama 18.1% oranında azalan oldu.

Anahtar bilgiler

-10.4%

Kazanç büyüme oranı

-4.0%

EPS büyüme oranı

Pharmaceuticals Sektör Büyümesi6.0%
Gelir büyüme oranı-18.1%
Özkaynak getirisi-13,511.3%
Net Marj-1,099.8%
Son Kazanç Güncellemesi30 Sep 2024

Yakın geçmiş performans güncellemeleri

Recent updates

Cara Therapeutics, Inc.'s (NASDAQ:CARA) Share Price Is Matching Sentiment Around Its Revenues

Nov 01
Cara Therapeutics, Inc.'s (NASDAQ:CARA) Share Price Is Matching Sentiment Around Its Revenues

Cara Therapeutics, Inc.'s (NASDAQ:CARA) Price Is Right But Growth Is Lacking After Shares Rocket 34%

Jul 18
Cara Therapeutics, Inc.'s (NASDAQ:CARA) Price Is Right But Growth Is Lacking After Shares Rocket 34%

We Think Cara Therapeutics, Inc.'s (NASDAQ:CARA) CEO Compensation Package Needs To Be Put Under A Microscope

May 29
We Think Cara Therapeutics, Inc.'s (NASDAQ:CARA) CEO Compensation Package Needs To Be Put Under A Microscope

Why Investors Shouldn't Be Surprised By Cara Therapeutics, Inc.'s (NASDAQ:CARA) Low P/S

May 25
Why Investors Shouldn't Be Surprised By Cara Therapeutics, Inc.'s (NASDAQ:CARA) Low P/S

We're A Little Worried About Cara Therapeutics' (NASDAQ:CARA) Cash Burn Rate

Feb 16
We're A Little Worried About Cara Therapeutics' (NASDAQ:CARA) Cash Burn Rate

The Market Doesn't Like What It Sees From Cara Therapeutics, Inc.'s (NASDAQ:CARA) Revenues Yet As Shares Tumble 43%

Dec 19
The Market Doesn't Like What It Sees From Cara Therapeutics, Inc.'s (NASDAQ:CARA) Revenues Yet As Shares Tumble 43%

News Flash: Analysts Just Made A Notable Upgrade To Their Cara Therapeutics, Inc. (NASDAQ:CARA) Forecasts

Nov 04
News Flash: Analysts Just Made A Notable Upgrade To Their Cara Therapeutics, Inc. (NASDAQ:CARA) Forecasts

Can Cara Therapeutics (NASDAQ:CARA) Afford To Invest In Growth?

Oct 25
Can Cara Therapeutics (NASDAQ:CARA) Afford To Invest In Growth?

Is Cara Therapeutics (NASDAQ:CARA) In A Good Position To Deliver On Growth Plans?

Jul 20
Is Cara Therapeutics (NASDAQ:CARA) In A Good Position To Deliver On Growth Plans?

Take Care Before Jumping Onto Cara Therapeutics, Inc. (NASDAQ:CARA) Even Though It's 30% Cheaper

Jun 04
Take Care Before Jumping Onto Cara Therapeutics, Inc. (NASDAQ:CARA) Even Though It's 30% Cheaper

News Flash: 8 Analysts Think Cara Therapeutics, Inc. (NASDAQ:CARA) Earnings Are Under Threat

Mar 11
News Flash: 8 Analysts Think Cara Therapeutics, Inc. (NASDAQ:CARA) Earnings Are Under Threat

Cara Therapeutics, Inc. (NASDAQ:CARA) Analysts Just Slashed Next Year's Estimates

Feb 15
Cara Therapeutics, Inc. (NASDAQ:CARA) Analysts Just Slashed Next Year's Estimates

We Think Cara Therapeutics (NASDAQ:CARA) Can Afford To Drive Business Growth

Feb 06
We Think Cara Therapeutics (NASDAQ:CARA) Can Afford To Drive Business Growth

We're Interested To See How Cara Therapeutics (NASDAQ:CARA) Uses Its Cash Hoard To Grow

Oct 18
We're Interested To See How Cara Therapeutics (NASDAQ:CARA) Uses Its Cash Hoard To Grow

Cara's partner files for Japanese approval of Korsuva to treat itch in hemodialysis patients

Sep 28

Cara Therapeutics hires new finance chief

Sep 12

Cara Therapeutics: All Eyes On Korsuva Launch Metrics

Sep 01

Cara, Vifor's Kapruvia gets approval in Switzerland to treat itch in hemodialysis patients

Aug 19

Cara Therapeutics GAAP EPS of -$0.08 beats by $0.18, revenue of $23M beats by $1.97M

Aug 08

Calls A Much Safer Way To Buy Cara Therapeutics

Jun 24

We're Not Very Worried About Cara Therapeutics' (NASDAQ:CARA) Cash Burn Rate

Jun 15
We're Not Very Worried About Cara Therapeutics' (NASDAQ:CARA) Cash Burn Rate

Brokers Are Upgrading Their Views On Cara Therapeutics, Inc. (NASDAQ:CARA) With These New Forecasts

May 12
Brokers Are Upgrading Their Views On Cara Therapeutics, Inc. (NASDAQ:CARA) With These New Forecasts

Taking A (Speculative) Position In Cara Therapeutics

Mar 21

Companies Like Cara Therapeutics (NASDAQ:CARA) Are In A Position To Invest In Growth

Mar 09
Companies Like Cara Therapeutics (NASDAQ:CARA) Are In A Position To Invest In Growth

Cara Therapeutics: De-Risked And Extremely Attractive

Dec 25

Checking Back In On Cara Therapeutics

Nov 01

Cara And IV Korsuva: Key Bull And Bear Investor Thoughts Going Into Upcoming PDUFA

Aug 21

The Consensus EPS Estimates For Cara Therapeutics, Inc. (NASDAQ:CARA) Just Fell Dramatically

Aug 15
The Consensus EPS Estimates For Cara Therapeutics, Inc. (NASDAQ:CARA) Just Fell Dramatically

Cara Therapeutics: 200% Upside Possible With FDA Approval

Aug 11

Gelir ve Gider Dağılımı

Cara Therapeutics nasıl para kazanır ve harcar. LTM bazında en son bildirilen kazançlara dayanmaktadır.


Kazanç ve Gelir Geçmişi

NasdaqCM:CARA Gelir, gider ve kazançlar (USD Millions )
TarihGelirKazançlarG+A GiderleriAr-Ge Giderleri
30 Sep 249-962733
30 Jun 2411-111270
31 Mar 2417-123290
31 Dec 2321-119290
30 Sep 2321-117290
30 Jun 2327-112290
31 Mar 2343-84290
31 Dec 2242-85310
30 Sep 2239-89360
30 Jun 2249-66350
31 Mar 2226-93340
31 Dec 2123-88310
30 Sep 211342425-6
30 Jun 211238250
31 Mar 2112914240
31 Dec 201358230
30 Sep 2028-99206
30 Jun 2024-115190
31 Mar 2024-113180
31 Dec 1920-106180
30 Sep 1921-98180
30 Jun 1920-85170
31 Mar 1918-79160
31 Dec 1813-74150
30 Sep 188-68140
30 Jun 183-61140
31 Mar 180-53130
31 Dec 171-58120
30 Sep 171-66110
30 Jun 171-6590
31 Mar 171-6990
31 Dec 160-5790
30 Sep 160-4590
30 Jun 163-3890
31 Mar 163-3180
31 Dec 154-2580
30 Sep 155-1970
30 Jun 153-2170
31 Mar 153-1970
31 Dec 143-1860
30 Sep 143-1651
30 Jun 143-1452
31 Mar 1412-643
31 Dec 1312-340

Kaliteli Kazançlar: CARA şu anda kârlı değil.

Büyüyen Kar Marjı: CARA şu anda kârlı değil.


Serbest Nakit Akışı ve Kazanç Analizi


Geçmiş Kazanç Büyüme Analizi

Kazanç Eğilimi: CARA kârlı değildir ve zararlar son 5 yılda yılda 10.4% oranında artmıştır.

Büyüme Hızlandırma: CARA 'un son bir yıldaki kazanç büyümesinin 5 yıllık ortalamasıyla karşılaştırılması mümkün değil çünkü şu anda kârlı değil

Kazançlar vs. Sektör: CARA kârlı olmadığından, geçmiş yıl kazanç büyümesinin Pharmaceuticals sektörüyle ( 54.6% ) karşılaştırılması zorlaşıyor.


Özkaynak Getirisi

Yüksek ROE: CARA hissesi şu anda kârlı olmadığından negatif Özsermaye Getirisi'ne ( -13511.32% ) sahiptir.


Varlık Getirisi


Kullanılan Sermaye Getirisi


Geçmişte güçlü performans gösteren şirketleri keşfedin